missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human MUC-1 Fc Chimera Alexa Fluor™ 488 Protein
Click to view available options
Quantità:
20 μg
Dimensione della confezione:
20µg
Descrizione
Measured by flow cytometry for its ability to bind anti-Human MUC-1 Monoclonal Antibody conjugated beads.The concentration of Recombinant human MUC-1 Chimera Alexa Fluor™ 488 (Catalog# AFG10332) that produces 50% of the binding response is 5.00-50.0 ng/mL
Specifica
Specifica
| Numero di accesso | P15941.3 |
| Da utilizzare con (applicazione) | Bioactivity |
| Formulazione | Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
| ID gene (immissione) | 4582 |
| Peso molecolare | M.W.-observed: 157-192 kDa, under reducing conditions., M.W.-theroretical: 60 kDa |
| Quantità | 20 μg |
| Sorgente | Human embryonic kidney cell, HEK293-derived human MUC-1 protein Human MUC-1 (Ser24-Ser380) (N-terminus) Accession # P15941.3 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) |
| Requisiti di stoccaggio | Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after opening. 3 months, -20°C to -70°C under sterile conditions after opening. |
| Concentrazione di endotossine | <1.0 EU / 1 μg of the protein by the LAL method. |
| Alias gene | Breast carcinoma-associated antigen DF3, Carcinoma-associated mucin, CD227, CD227 antigen, DF3 antigen, EMA, episialin, H23 antigen, H23AG, KL-6, MAM6, MUC-1, MUC1/ZD, mucin 1, cell surface associated, mucin 1, transmembrane, mucin-1, Peanut-reactive urinary mucin, PEM, PEMMUC-1/SEC, PEMT, Polymorphic epithelial mucin, PUMMUC-1/X, tumor associated epithelial mucin, Tumor-associated epithelial membrane antigen, Tumor-associated mucin |
| Vedi altri risultati |
Correzione del contenuto del prodotto
Fornite il vostro feedback sul contenuto del prodotto compilando il modulo sottostante.
Titolo del prodotto
Individuate un'opportunità di miglioramento?Condividi una correzione di contenuto